Formosa Pharmaceuticals, Inc.

TWSE:6838 Stock Report

Market Cap: NT$5.7b

Formosa Pharmaceuticals Past Earnings Performance

Past criteria checks 0/6

Formosa Pharmaceuticals's earnings have been declining at an average annual rate of -3.6%, while the Pharmaceuticals industry saw earnings growing at 8.2% annually. Revenues have been growing at an average rate of 64.8% per year.

Key information

-3.6%

Earnings growth rate

10.2%

EPS growth rate

Pharmaceuticals Industry Growth18.5%
Revenue growth rate64.8%
Return on equity-12.8%
Net Margin-149.1%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Formosa Pharmaceuticals makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

TWSE:6838 Revenue, expenses and earnings (TWD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 24137-20562255
30 Jun 24134-29960287
31 Mar 2482-31250279
31 Dec 2331-32240270
30 Sep 2331-37836312
30 Jun 2332-33933321
31 Mar 2316-37229339
31 Dec 221-40626356
30 Sep 221-41625368
30 Jun 221-41922392
31 Mar 2215-41022390
31 Dec 2129-40121388
30 Sep 2128-34621334
30 Jun 2128-29021281
31 Mar 2114-25519249
31 Dec 200-22017216
31 Dec 191-1978191

Quality Earnings: 6838 is currently unprofitable.

Growing Profit Margin: 6838 is currently unprofitable.


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 6838 is unprofitable, and losses have increased over the past 5 years at a rate of 3.6% per year.

Accelerating Growth: Unable to compare 6838's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: 6838 is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (11.9%).


Return on Equity

High ROE: 6838 has a negative Return on Equity (-12.78%), as it is currently unprofitable.


Return on Assets


Return on Capital Employed


Discover strong past performing companies

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/21 12:42
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/30
Annual Earnings2023/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Formosa Pharmaceuticals, Inc. is covered by 0 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution